Q-omics provides the consensus-scored METTL5 profile across patient tissues and cancer cell-line models. METTL5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, METTL5 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, METTL5 RNA expression shows 19,433 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where METTL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL5 survival associations across molecular data types. METTL5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL5 RNA expression–survival associations across cancer types. High METTL5 expression shows unfavorable associations in KIRP, ACC, SCLC, LUAD, LIHC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for METTL5 RNA expression.
This table summarizes METTL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for METTL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL5 shows higher tumor expression in HNSC, KIRC, COAD, LIHC, LUSC and LUAD. The HNSC box plot shows higher METTL5 RNA expression in tumor versus normal tissue (log2 FC = +1.117, t-test p < 0.001).
This table shows molecular features associated with METTL5 in patient tissues and cancer cell lines. In patient samples, METTL5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
